BBT-4437 / Bridge Biotherap - LARVOL DELTA

Bridge Bio presents anti-cancer project poster at the International Association for Cancer Research conference [Google translation] (Medifonews) - "On the 14th local time, the company disclosed preclinical research data and future clinical plans for BBT-207, which is being developed as a lung cancer clinical project, and BBT-207, a new solid cancer treatment candidate discovered by itself through its US subsidiary Boston Discovery Center (BDC)....In addition, the drug's inhibitory effect on brain metastasis and improvement in survival rate were confirmed through an animal model based on lung cancer cells derived from patients....According to the published poster, BBT-4437 has been shown to bind to the TEAD family broadly (pan-TEAD binder) and selectively (selectivity) through various in vitro studies, including reporter gene assay....In animal model experiments, BBT-4437 also showed excellent antitumor activity."

Preclinical • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Solid Tumor